Clinical Trial Update: Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating reduced-intensity, partially HLA-mismatched bone marrow transplantation for hematologic malignancies; the study is completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Hematologic Malignancies | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2026-02-18